tiprankstipranks
Trending News
More News >

Tsumura & Co. Completes Interim Financial Review for Q3 2025

Story Highlights
Tsumura & Co. Completes Interim Financial Review for Q3 2025

Tsumura & Co ( (JP:4540) ) has shared an announcement.

Tsumura & Co. has announced the completion of an interim review of its consolidated financial results for the third quarter ending March 31, 2025. The review, conducted by certified public accountants, confirmed no changes to the financial statements released earlier. This announcement is part of the company’s ongoing efforts related to a share offering, highlighting its commitment to transparency and compliance with financial regulations.

More about Tsumura & Co

Tsumura & Co. operates in the pharmaceutical industry, primarily focusing on the production and distribution of traditional Japanese Kampo medicines. The company is listed on the TSE Prime Market and is headquartered in Tokyo, Japan.

YTD Price Performance: -4.59%

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $2.19B

For a thorough assessment of 4540 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App